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doi:10.1016/j.ejvs.2010.03.003Abstract Background: Atrial fibrillation (AF) is a significant risk factor for cardiovascular (CV)
mortality. This study aims to evaluate the prognostic implication of AF in patients with periph-
eral arterial disease (PAD).
Methods: The International Reduction of Atherothrombosis for Continued Health (REACH)
Registry included 23,542 outpatients in Europe with established coronary artery disease, cere-
brovascular disease (CVD), PAD and/or 3 risk factors. Of these, 3753 patients had symptom-
atic PAD. CV risk factors were determined at baseline. Study end point was a combination of7034613; fax: þ31107034957.
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10 T.A. Winkel et al.cardiac death, non-fatal myocardial infarction (MI) and stroke (CV events) during 2 years of
follow-up. Cox regression analysis adjusted for age, gender and other risk factors (i.e., conges-
tive heart failure, coronary artery re-vascularisation, coronary artery bypass grafting (CABG),
MI, hypertension, stroke, current smoking and diabetes) was used.
Results: Of 3753 PAD patients, 392 (10%) were known to have AF. Patients with AF were older
and had a higher prevalence of CVD, diabetes and hypertension. Long-term CV mortality
occurred in 5.6% of patients with AF and in 1.6% of those without AF (p< 0.001). Multivariable
analyses showed that AF was an independent predictor of late CV events (hazard ratio (HR):
1.5; 95% confidence interval (CI): 1.09e2.0).
Conclusion: AF is common in European patients with symptomatic PAD and is independently
associated with a worse 2-year CV outcome.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Atherothrombosis is a progressive, generalised disorder
that affects large- and medium-sized arteries throughout
the arterial tree, with many clinically acute or chronic
manifestations.1 In the peripheral arteries, athero-
thrombosis can contribute to the progression of peripheral
arterial disease (PAD) producing intermittent claudication,
as well as ischaemic necrosis and, potentially, loss of the
limb. Occurrence of an arterial ischaemic event due to
atherothrombosis implies that a similar pathological
process may have already affected other arterial territo-
ries.2,3 Patients with a first ischaemic event are at high risk
of developing further atherothrombotic events. The prev-
alence of additional risk factors, such as atrial fibrillation
(AF), increases the risk of atherothrombotic events, as
shown in the AF sub-study of the REACH Registry.4,5
AF is gaining attention from the medical community as
its epidemiological weight is increasing.6 AF is the most
common cardiac arrhythmia in clinical practice, with >4.5
million affected in Europe. Most patients with AF are >65
years of age and present with many co-morbidities, in
particular, hypertension (37%), heart failure (23%), coro-
nary artery disease (18%) and diabetes (15%).7 The preva-
lence of AF is estimated to increase due to the ageing
general population.6,7 AF is a major cause of morbidity,
being associated with left ventricular dysfunction,
decreased exercise tolerance and quality of life8 as well as
a twofold-increased risk in cardiac mortality.7 In the
Copenhagen City Heart Study, a 60% increase in hospital
admissions for AF, independent of changes in known risk
factors, was reported during the last 10e20 years.9 Much of
the morbidity and mortality associated with AF is attributed
to the thromboembolic complications, resulting in
increased risk of cardiovascular (CV) death,4 as well as
ischaemic stroke.7 Goto et al. reported worse 1-year CV
events in patients with atherothrombosis and AF.4
The aim of the analysis in this article was to evaluate the
prevalence and prognostic implication of AF among Euro-
pean patients with symptomatic PAD, focussing on risk-
factor profiles, medication use and 2-year rates of CV
death, myocardial infarction (MI) and stroke in AF and non-
AF patients. Data were based on the REduction of Athero-
thrombosis for Continued Health (REACH) Registry, which is
a large-scale, prospective, international cohort of stable
subjects with or at high risk of atherothrombotic
complications.3,10Methods
Database of the REACH Registry
Full details of the rationale and design of the REACH
Registry have been described elsewhere.10 In brief, it is an
international, prospective, observational registry designed
to provide up to 24 months of clinical follow-up of >68,000
outpatients from w5000 sites in 44 countries; it has
recently been extended to provide up to 48 months of
clinical follow-up.3 Patients enrolled were 45 years of age
with at least one of the following four criteria: documented
symptomatic (1) coronary artery disease (CAD; angina, MI or
angioplasty/stent/bypass), (2) cerebrovascular disease
(CVD; ischaemic stroke or transient ischaemic attack (TIA)),
(3) peripheral arterial disease (PAD; historical or current
intermittent claudication associated with ankleebrachial
index (ABI) <0.9) or (4) at least three pre-defined athero-
thrombotic risk factors.10 Patients already in a clinical trial,
hospitalised patients or those who might have difficulty
returning for a follow-up visit were excluded. Subjects
were recruited consecutively, mainly by general practi-
tioners (42%) and internists (32%).3 They were evaluated at
baseline for a range of demographic, medical and labora-
tory characteristics, prior to being re-evaluated annually
for up to 48 months post-baseline to ascertain whether they
experienced any clinical events or hospitalisations. The
institutional review board in each participating country
approved the study design and all patients included in the
analysis provided signed, informed consent. In this manu-
script, we focus on the difference in AF and non-AF patients
with symptomatic PAD in the European population, which
included 23,542 stable outpatients.Definition of AF
All patients were classified based on the presence or
absence of AF, at the time of enrolment.4 If participating
physicians could not confirm whether patients had a history
of AF, the patients were classified as ‘unknown’ and
excluded from this analysis.
Patients with AF were also stratified using the CHADS2
risk score in which one point is assigned to patients with
a history of congestive heart failure (CHF), hypertension,
diabetes mellitus, age 75 years and two points for
a history of stroke or TIA.11
Prognosis of Atrial Fibrillation in Patients with Symptomatic Peripheral Arterial Disease 11Study outcomes
There were two primary study outcomes. The first was
a combined end point of non-fatal stroke, non-fatal MI and
CV death assessed at 21 3 months from enrolment. The
second was a combined end point of CV death, non-fatal
stroke, non-fatal MI, vascular interventions and hospital-
isations for atherothrombotic events at 2 years of follow-
up. The limb outcome and individual clinical events
described constituted the pre-defined secondary end points
of the study. Events were not adjudicated; however,
reports of ischaemic stroke and TIA had to be sourced from
a neurologist or hospital to ensure a reliable diagnosis.Table 1 Baseline characteristics.
Patient characteristics
Age, years
Female, %
BMI (kg/m2)
Current smoker, %
Previous history of
Smoking, %
Stable angina, %
Unstable angina, %
Myocardial Infarction, %
Coronary angioplasty/stenting, %
Coronary artery bypass graft, %
TIA, %
Ischaemic stroke, %
Diabetes, %
Hypertension (despite therapy for minimally 3 months), %
Hypercholesterolemia (in treatment), %
Congestive heart failure, %
Aortic valve stenosis, %
Asymptomatic carotid stenosis (70%), %
Carotid surgery, %
Abdominal aortic aneurysm, %
Previous history of PAD
ABI< 0.9, %
Lower limb graft, %
Lower limb amputation, %
Medications
ASA, %
Other anti-platelet agent, %
ASA and other anti-platelet agent, %
Oral anticoagulants, %
At least 1 anti-thrombotic agent, %
Oral anticoagulant and ASA, %
NSAIDs, %
Statins, %
Calcium channel blockers, %
Beta blockers, %
Nitrates, %
Diuretics, %
ACE-Inhibitors, %
TIAZ transient ischaemic attack, PADZ peripheral arterial disea
NSAIDZ non-steroidal anti-inflammatory drug, ACEZ angiotensin-conStatistical analysis
Continuous variables are expressed as mean standard
deviation (SD) compared by using the ManneWhitneyeWil-
coxon test. Categorical variables are expressed as numbers
and percentages and analysed using the chi-square test. A
p-value of <0.01 was considered statistically significant (for
Tables 1e3) and no allowance for multiple hypothesis
testing was made. The relationship between a history of AF
and the combined end point at 2 years of follow-up was
assessed with multivariate Cox regression analyses, cor-
recting for age, gender, and risk factors (i.e., CHF, coronary
artery re-vascularisation, CABG, MI, hypertension, stroke,With AF (nZ 392) Without AF (nZ 3263) p-value
71.6 9.1 67.2 9.6 <0.001
25.6 24.8 0.74
27.4 4.4 27.1 4.5 0.29
18.6 29.2 <0.001
65.0 78.2 <0.001
40.4 27.2 <0.001
15.6 9.8 <0.001
33.2 24.9 <0.001
20.5 16.3 <0.05
19.6 15.5 <0.05
20.2 13.5 <0.001
19.0 14.1 <0.01
43.4 36.5 <0.01
61.0 52.0 <0.001
60.2 64.9 0.07
43.5 11.2 <0.001
11.2 3.5 <0.001
22.9 15.1 <0.01
7.2 6.6 0.65
8.9 6.0 <0.05
89.5 90.2 0.70
46.4 51.0 0.09
11.2 10.8 0.78
42.6 61.5 <0.001
20.2 34.4 <0.001
7.9 10.8 0.08
52.3 10.1 <0.001
95.9 92.1 <0.01
8.4 2.5 <0.001
13.0 7.5 <0.001
60.7 62.6 0.47
31.1 33.0 0.45
48.0 38.3 <0.001
34.7 21.4 <0.001
62.8 40.1 <0.001
73.0 60.6 <0.001
se, ABIZ ankle brachial index, ASAZ acetyl salicylic acid,
verting enzyme, and BMIZ Body Mass Index.
Table 2 Comparison between patients with atrial fibrillation and the use of oral anticoagulants.
AFþ Yes anticoagulants
(nZ 222)
AFþ No anticoagulants
(nZ 205)
p-value
Patient characteristics
Age, years 72.3 8.6 71.4 9.6 0.17
Female, % 27.5 22.5 0.24
BMI (kg/m2) 27.4 4.3 27.2 4.5 0.45
Current smoker, % 12.0 27.7 <0.001
Previous history of
Smoking, % 51.4 40.5 <0.05
Stable angina, % 35.9 42.8 0.15
Unstable angina, % 19.6 13.0 0.07
Myocardial Infarction, % 32.9 34.5 0.73
Coronary angioplasty/stenting, % 21.3 19.5 0.65
Coronary artery bypass graft, % 19.9 19.5 0.92
TIA, % 20.5 19.5 0.79
Ischaemic stroke, % 22.1 15.8 0.10
Hypertension (despite therapy for minimally 3 months), % 58.1 63.4 0.26
Hypercholesterolemia (in treatment), % 56.8 60.5 0.43
Congestive heart failure, % 47.5 36.9 <0.05
Aortic valve stenosis, % 11.2 10.8 0.91
Asymptomatic carotid stenosis (70%), % 22.2 21.5 0.89
Carotid surgery, % 7.2 7.4 0.95
Abdominal aortic aneurysm, % 7.3 9.6 0.43
Previous history of PAD
ABI< 0.9, % 89.3 89.7 0.91
Lower limb graft, % 50.0 42.4 0.12
Lower limb amputation, % 11.7 12.2 0.88
Medications
ASA, % 16.2 70.7 <0.001
Other anti-platelet agent, % 9.5 32.2 <0.001
Oral anticoagulants, % 100 0
At least 1 anti-thrombotic agent, % 100 91.2 <0.001
NSAIDs, % 9 17.1 <0.05
Statins, % 59.0 59.0 1.00
Calcium channel blockers, % 28.4 35.6 0.11
Beta blockers, % 46.8 44.4 0.61
Nitrates, % 32.0 40.5 0.07
Diuretics, % 66.2 60.0 0.18
ACE-Inhibitors, % 59.9 56.6 0.49
TIAZ transient ischaemic attack, PADZ peripheral arterial disease, ABIZ ankle brachial index, ASAZ acetyl salicylic acid,
NSAIDZ non-steroidal anti-inflammatory drug, and ACEZ angiotensin-converting enzyme.
12 T.A. Winkel et al.current smoking and diabetes). Hazard Ratios (HR) are
given with 95% confidence intervals (CI). A p-value of <0.05
(two-sided) was considered significant. All analyses were
performed using the Statistical Analysis Software version 9
(SAS v.9; SAS Institute Inc., Cary, NC, USA).
Results
The study population consisted of 23,542 European patients
with atherothrombosis. Of these, 3753 patients had symp-
tomatic PAD. Baseline information regarding a history of AF
was available from 3655 patients and represents the anal-
ysis sample. The baseline characteristics and medication
use are listed in Table 1. The mean age at baseline was
67.7 9.6 years and 75.1% of the PAD patients were male.The prevalence of AF in the PAD patient group was 10.4%
(nZ 392). Patients with AF were significantly older, more
often had a history of angina pectoris, MI, ischaemic stroke,
TIA, CHF, aortic valve stenosis, CVD, diabetes, hypertension
and included a lower prevalence of smokers.
In general, patients with AF received more medication
as compared to those without AF. Use of anti-thrombotics
was high among patients with AF, with w96% receiving at
least one anti-thrombotic agent. Significantly more patients
with AF used non-steroidal anti-inflammatory drugs, beta
blockers, nitrates, diuretics and angiotensin-converting
enzyme (ACE) inhibitors. There were no differences
between statin and calcium channel blocker use in AF vs.
non-AF patients. Approximately half (52.3%) of the patients
with AF were treated with oral anticoagulants and 42.6%
Table 3 Long-term clinical outcome (2-year follow-up).
Yes AF
(nZ 392)
No AF
(nZ 3263)
p-Value
Cardiovascular death, % 5.6 1.6 <0.001
Non-fatal stroke, % 4.1 2.8 0.16
Non-fatal MI, % 4.6 1.8 <0.001
CV events 12.5 6.0 <0.001
CV events
and hospitalisation
37.0 25.5 <0.001
MIZmyocardial infarction, and Combined end pointZ cardio-
vascular (CV) events (cardiovascular death, non-fatal stroke,
non-fatal MI). Figure 1 CV events (cardiovascular death, MI, and stroke)
occurred in 12.5% of PAD patients with AF compared to 6.0% in
those without AF (p< 0.001).
Table 4 Multivariate analyses for long-term cardiovas-
cular (CV) events, adjusting for age, gender and risk factors
(diabetes, hypertension, congestive heart failure, coronary
artery revascularization, CABG, stroke, current smoking and
myocardial infarction).
Hazard ratio
(95% confidence
interval)
Atrial fibrillation 1.48 (1.09e2.02)
Age 1.03 (1.01e1.04)
Female 0.98 (0.75e1.28)
Diabetes 1.44 (1.14e1.82)
Hypertension 1.06 (0.78e1.45)
Congestive heart failure 1.73 (1.30e2.30)
Coronary angioplasty/stenting 0.76 (0.54e1.08)
CABG 1.13 (0.81e1.57)
Ischaemic stroke 2.20 (1.70e2.84)
Myocardial infarction 1.25 (0.94e1.67)
Current smoking 1.43 (1.09e1.88)
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with a history of AF and no use of anticoagulant agents
more often had a history of current smoking.
In addition, in the current analyses, it was calculated
that patients with AF had a significantly higher CHADS2 risk
score as compared to those without AF (mean CHADS2 score
in AF vs. non-AF patients; 2.1 1.4 vs. 1.9 1.3, general
linear model p< 0.001).
Study outcomes
As shown in Table 3, the presence of AF at baseline was
associated with higher rates of 2-year adverse CV outcomes
(i.e., combined CV death, MI and stroke). The all-cause
(7.7%) and CV mortality (5.6%) rates of patients with AF
were substantially higher than in non-AF patients (2.5% and
1.6%, respectively; p-value< 0.001). In the 2 years after
the baseline visit, there was a significantly higher incidence
of CHF (16.8% vs. 5.1%, respectively), unstable angina
(11.6% vs. 7%, respectively) and bleeding requiring hospi-
talisation and transfusion (2.7% vs. 1.4%, respectively) in
patients with AF compared to those without AF. Worsening
of claudication related to PAD was not more evident in the
AF vs. non-AF patients (27.1% vs. 27.4%, pZ 0.89, respec-
tively). On the other hand, during the 2-year follow-up
period, patients with AF more often underwent amputa-
tions affecting the lower limb as compared to those
without AF (4.8% vs. 2.1%, p< 0.01, respectively). There
were no differences between the two groups in combined
end point and/or re-vascularisation during follow-up
(patients with AF 27.1% vs. non-AF 23.7%, pZ 0.13,
respectively).
The combined end point of CV events occurred in 49
(12.5%) patients with a previous history of AF and 196 (6.0%)
patients in those without AF (Table 3). Patients with AF also
had a higher incidence of the CV events and/or hospital-
isation for atherothrombotic events than those without AF
(37% vs. 25.5%, p-value< 0.001, Table 3). As shown in
Fig. 1, the presence of AF at baseline was associated with
a significantly higher rate of CV events during 2 years of
follow-up. In multivariable analyses, after adjusting for
age, gender and risk factors, AF was an independent
predictor of long-term CV events (HR: 1.48; 95% CI:
1.09e2.02; Table 4). Other risk factors that were associated
with 2-year CV events were: age, diabetes, CHF, current
smoking and stroke.Discussion
This study demonstrates that AF is a common condition in
European patients with symptomatic PAD and could indi-
cate patients with extensive atherothrombosis. Further-
more, AF is an independent predictor of late adverse
outcome with a 1.5-fold increase of CV mortality in patients
with PAD.
Incidence, prevalence and risk factors associated
with AF
The prevalence of AF is 0.4e1% in the general pop-
ulation.6,12 In the coming years, this prevalence will likely
increase due to the ageing of the general population,
a rising prevalence of CV disease and more frequent diag-
nosis of AF through use of more specific ambulatory moni-
toring devices.7 Furthermore, it has to be noticed that the
prevalence of AF is an underestimation of this type of
arrhythmia since a great proportion of patients are
asymptomatic.7 The AnTicoagulation and Risk Factors In
Atrial Fibrillation (ATRIA) study assembled a contemporary
14 T.A. Winkel et al.cohort of 17,974 patients with non-transient AF and found
that AF affects one in 25 adults 60 years of age and nearly
one in 10 adults 80 years.6 However, in patients with
established atherothrombotic disease, such as PAD,13,14 the
prevalence and incidence of AF is likely higher,7,15 as
previously demonstrated in the AF sub-study of the REACH
Registry.4 This high prevalence of AF in PAD patients is also
confirmed in the current European focussed AF sub-study as
we observed a prevalence of 10.4%. When comparing the
baseline characteristics of the ATRIA study 6 and the REACH
Registry population, it is evident that the current patients
have more number of atherothrombotic risk factors. These
data supported the concept that the prevalence of AF is
higher in patients with symptomatic atherothrombosis.4
This process could also be vice versa, that is, due to
acute thromboembolic occlusions or progression of the
atherothrombotic process which enhances the obstruction
of blood flow to the peripheral arteries and could cause
intermittent claudication.2,16 However, it is hard to define
which process precedes the other since these will often be
present simultaneously. The Framingham heart study
demonstrated that gender, age, diabetes, hypertension,
CHF and cardiac valve disease were independent risk
factors for AF.17 Previous studies have also identified non-
cardiac precipitants for AF, for example, obesity,18,19 thy-
rotoxicosis,20e22 alcohol use,20,23 severe infections20,24 and
pulmonary pathology.20e22 These general and pathophysi-
ology risk factors have also been confirmed in the current
data, where PAD patients with AF were significantly older,
more often had a history of angina pectoris, MI, CHF, aortic
valve stenosis, CVD, diabetes and hypertension.
Identification of AF patients at increased risk of
adverse outcome
Patients with lone AF were initially thought to have a good
prognosis with respect to thromboembolism and mortality,
but more recent data suggest that it is associated with
higher mortality.6,24 Our data, along with previously pub-
lished AF sub-study of the REACH Registry,4 demonstrated
that AF is an independent predictor of long-term CV events
in patients with PAD. Goto et al. assessed the distribution of
the CHADS211 score in patients with and at high risk of
atherothrombosis and its relation to cerebrovascular
outcomes.11,25 They concluded that, in patients with AF, CV
events, especially non-fatal stroke, and the combined end
point of CV death/MI/stroke, were more frequent in the
higher CHADS2 score subgroup (the rate of CV death/MI/
stroke varied from 3.9% in the CHADS2 score-0 group to
12.4% in the CHADS2 score-6 group).4 In the current study,
the calculated CHADS2 risk score was also significantly
differing between the two groups, with a higher CHADS2
score in those patients with AF as compared to those
without AF.
Management of patients with AF
Managing patients with AF and the associated conditions is
a major challenge. Restoration and maintenance of sinus
rhythm in patients with AF is clearly an important thera-
peutic goal,26 in combination with anti-thrombotic therapyto decrease the rate of embolic complications caused by AF.
The efficacy, safety and shortcomings of current anti-
thrombotic therapies for patients with AF are an ongoing
discussion. Recent clinical trials comparing rhythm and rate
control have suggested that effective anticoagulation and
heart-rate control is not inferior to rhythm control.6,26
Current guidelines recommend warfarin for patients who
have AF and are at risk of stroke.7 The combination of anti-
platelet and anticoagulant therapy (triple therapy) is often
used in patients with established atherothrombotic disease
and AF.7,27 However, the Warfarin anti-platelet Vascular
Evaluation (WAVE) trial randomised patients with PAD to
receive oral anticoagulant (OAC) plus anti-platelet therapy
or anti-platelet therapy alone and found that the combina-
tion of an OAC and anti-platelet therapy was not more
effective than anti-platelet therapy alone in preventing
major CV complications and was associated with an increase
in life-threatening bleeding.28,29 The use of combined
therapy is expected to become more prominent, yet is also
associated with a significantly increased bleeding risk.27 The
rate of major bleeding complications may be kept accept-
ably low even in elderly AF patients, provided there is
a careful management of anticoagulation.30 Our data,
however, show that only 50% of PAD patients with AF
received oral anticoagulants. This confirms earlier studies
showing an under-treatment in AF patients.3,4 In the study
from REACH on patients with AF in the global population by
Goto et al., the use of oral anticoagulants was low even in
patients at high risk of stroke.4 An explanation for this low
use of oral anticoagulants in the REACH population was
coupled to the markedly high background use of anti-
platelet agents.4 In the current results of the REACH data,
2-year CV outcomes confirms that patients with AF more
often had bleeding requiring hospitalisation, which could be
speculated to be associated with using combined therapy.
In a more recent non-inferiority trial by Connolly et al.,
the new, oral, direct thrombin-inhibitor dabigatran,
administered at a dose of 150 mg in patients with AF, was
associated with lower rates of stroke and systemic embo-
lism but similar rates of major haemorrhage as compared
with warfarin.31 These results could likely increase the
intake of these new thrombin inhibitors since these are less
cumbersome than vitamin-K antagonists.31
Patients with PAD should receive beta blockers, statins
and, most commonly, an anti-platelet agent.32
However, as is also shown in the current study, patients
with PAD are largely under-treated.
Limitations
There are several limitations to these data. First, there are
no data on the classification of AF (paroxysmal, persistent or
chronic), duration of AF or use of anti-arrhythmic agents
available. The specification of the AF classification could
partly help explain the therapeutic regiments. Furthermore,
no laboratory markers were tested at baseline, which could
have helped to make more specifications in a predictive
model for risk factors for AF, for example, inflammation
markers and N-terminal pro-B-type natriuretic peptide. In
addition, due to the exclusion of patients without an
apparent or certain history of AF by participating physicians,
it could well be that patients with AF and PAD have been
Prognosis of Atrial Fibrillation in Patients with Symptomatic Peripheral Arterial Disease 15excluded from these analyses, with the possibility of
underestimating the true prevalence of AF in European PAD
patients.
Conclusion
AF is common in European patients with symptomatic PAD
and is independently associated with a worse 2-year CV
outcome. Current guidelines for AF management should be
observed to manage the increased risk of CV morbidity and
mortality.
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